Business
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with IND Filing on Track for 2H 2022 SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced the publication of preclinical research in the July 6 issue of Science Translational Medicine. The article, titled “Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy,” describes the discovery of histone deacetylase 6 (HDAC6) as a promising therapeutic target. These insights led to the development of the company’s lead small molecule candidate, TN-301, a highly selective HDAC6 inhibitor initially being developed for the potential treatment of heart failure with preserved ejection fraction (HFpEF). \"While cardiovascular diseases remain the leading cause of death worldwide, innovation in therapeutic discovery has suffered from the challenge of identifying targets with validation in human tissue that can address underlying mechanisms of heart disease. The success of our approach using disease models based on human cells plus machine learning algorithms to discover promising new therapeutic targets for heart diseases provides reason to believe that this methodology may be broadly applicable to accelerating target and drug discovery of other disease-modifying therapies,” said Timothy Hoey, Ph.D., Chief Scientific Officer of Tenaya Therapeutics. “Research presented in this paper highlight the exquisite target selectivity and cardioprotective qualities of our HDAC6 inhibitors. We look forward to advancing TN-301, the first product candidate in our pipeline to be discovered and validated using this approach, into clinical studies.” Key Research FindingsThe publication in Science Translational Medicine details Tenaya’s distinct Precision Medicine platform approach of applying phenotypic screening and deep learning to human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) disease models. Tenaya developed and validated a BAG3 knock-down human iPSC-CM model of dil...